# Davunetide

Canonical source: https://retacompare.com/encyclopedia/davunetide

Stabilizes microtubules via tubulin binding, particularly in tauopathy models.

Reference facts

Also known asNAP, AL-108, NAPVSIPQCategoryNootropic & CognitiveMechanism of actionStabilizes microtubules via tubulin binding, particularly in tauopathy models.TargetsTubulin / microtubulesIndications under research or approvedPhase 2/3 in progressive supranuclear palsy (failed primary endpoint 2014); ongoing research in ADNP syndromeRegulatory status (reference entry)InvestigationalHalf-lifeMinutes (intranasal)SequenceNAPVSIPQSequence notesOctapeptide active fragment of activity-dependent neuroprotective protein (ADNP).Molecular weight (Da)825Originator / sponsorOriginally Allon TherapeuticsFirst reported1999
    Primary References

Boxer et al., Lancet Neurol 2014 (Davunetide PSP)


    Explore research articles about Davunetide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- Boxer et al., Lancet Neurol 2014 (Davunetide PSP): https://pubmed.ncbi.nlm.nih.gov/25304059/